All In Biotech

Free tool

FAERS Monitor: Vimizim

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125460 or its brand name (Vimizim, Elosulfase Alfa). Reports on generic versions are filed under their own applications.

Reports

5,517

Serious

2,246

41% of reports

Hospitalization

1,167

Death reported

134

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia742
  • cough353
  • vomiting333
  • malaise287
  • headache261
  • pain241
  • dyspnoea238
  • nausea228
  • fatigue202
  • nasopharyngitis199
  • pneumonia172
  • oxygen saturation decreased155
  • product dose omission155
  • pain in extremity146
  • arthralgia140

Reports by year received

View as table
YearReports
2014151
2015436
2016526
2017445
2018440
2019470
2020406
2021475
2022465
2023467
2024425
2025460
2026351

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,642 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oxygen saturation decreasedSignal15510.59.01,329
product dose omissionSignal1559.17.81,106
pyrexiaSignal7428.27.74,745
coughSignal3534.84.31,072
nasopharyngitisSignal1994.13.6470
vomitingSignal3332.72.4363
malaiseSignal2872.52.2261
pneumoniaSignal1722.01.790
pain in extremity1461.91.661
dyspnoea2381.61.455
headache2611.61.458
pain2411.51.340
arthralgia1401.31.19
nausea2281.11.02
fatigue2021.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.